Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Liver Neoplasms 1Liver Diseases 1Digestive System Neoplasms 1Digestive System Diseases 1Carcinoma, Hepatocellular 1Carcinoma 1Adenocarcinoma 1

Interventions

Bevacizumab 3napabucasin 2Leucovorin 2Irinotecan 2Gemcitabine 2Fluorouracil 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2trifluridine tipiracil drug combination 1linifanib 1enoxaparin sodium 1encorafenib 1Surveys and Questionnaires 1Sorafenib 1Oxaliplatin 1Oviposition 1Levoleucovorin 1Injections 1Hydromorphone 1Fentanyl 1Drug Therapy 1Drainage 1Dalteparin 1Cetuximab 1Capecitabine 1Bupivacaine 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Digestive System Diseases × linifanib × Clear all
NCT01009593 2012-09-10

Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Abbott

Phase 3 Terminated
1,035 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡